摘要
目的探讨阿托伐他汀对单纯急性冠脉综合征(ACS)患者及ACS合并糖尿病(DM)患者血糖代谢的影响。方法筛选2012年1—8月在我院急诊综合病房住院的ACS患者116例,分为ACS组(62例)和ACS+DM组(54例),入院开始口服阿托伐他汀20 mg,1次/晚,以入院时测定的血清空腹血糖(FBG)与糖化血红蛋白(HbA1c)为基线值,3个月后在我院门诊复查FBG和HbA1c,并与入院时的基线值进行比较。结果口服阿托伐他汀3个月后,ACS患者FBG水平由(5.5±0.4)mmol/L升至(5.6±0.6)mmol/L,HbA1c由(5.6±0.4)%降至(5.7±0.5)%,ACS+DM患者的FBG水平由(7.0±2.1)mmol/L降至(6.8±1.4)mmol/L,HbA1c由(7.4±1.4)%降至(7.3±1.3)%,但差异均无统计学意义(P>0.05)。结论短期常规剂量阿托伐他汀治疗可以轻微升高单纯ACS患者的血糖水平,而对于ACS+DM患者,阿托伐他汀可以轻微降低其血糖水平,其效果有待继续研究。
Objective To investigate the effect of atorvastatin on glycometabolism in patients with acute coronary syn- drome (ACS) or ACS combined with diabetes mellitus (DM). Methods A total of 116 ACS patients admitted into Department of Emergency of our hospital between January 2012 and August 2012 were divided into an ACS group (n =62) and an ACS + DM group (n = 54). The subjects were given oral administration of atorvastatin 20 mg q. n. from admission. The levels of fast- ing blood glucose (FBG) and HbA1o were determined upon admission and in follow - up examination three months later. Results After oral administration of atorvastatin 20 mg q. n. for three months, the levels of FBG and HbA1o of patients in ACS group in- creased from (5.5± 0. 4) mmol/L to (5.6 ± 0. 6) mmol/L, from (5.6 ± 0. 4) % to (5.7 ± 0. 5 ) %, respectively; And those of patients in the ACS + DM group decreased from (7. 0±2. 1 ) mmol/L to (6. 8± 1.4) mmol/L, from (7.4 ± 1.4)% to (7.3± 1.3) %, respectively. However, the changes were of no statistical significance (P 〉0. 05). Conclusion Short - term administration of routine dose atorvastatin can elevate FBG level in patients with ACS, but reduce FBG level in patients with ACS combined with DM.
出处
《中国全科医学》
CAS
CSCD
北大核心
2013年第14期1623-1625,共3页
Chinese General Practice
关键词
阿托伐他汀
急性冠脉综合征
空腹血糖
血红蛋白
糖基化
糖尿病
Atorvastatin
Acute coronary syndrome
Fasting blood glucose
Hemoglobin A, glycosylated
DiabetesmeUitus